Lonza to establish large-scale, commercial drug product fill & finish facility in Stein (CH)

SIX-listed Lonza Group AG announced that it plans to construct a large-scale, commercial drug product fill & finish facility in Stein, Switzerland. The investment will allow Lonza to provide customers with a complete and integrated end-to-end solution that includes commercial drug manufacturing for large-scale market supply. The new facility will be funded by an investment of approx. CHF 500 million and is expected to be completed in 2026.

Lenz & Staehelin is advising Lonza in this transaction. The team includes Fabiano Menghini, Rebecca Rötheli, Noémie Ammann and Jan Küng.